•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026
IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Medical Ltd. (NASDAQ:ICCM) Stock Now Rated “Hold” by Sell-Side Analysts
Reviewing IceCure Medical (NASDAQ:ICCM) & Precision Optics (NASDAQ:POCI)
IceCure Secures China NMPA Approval for ProSense Cryoablation System
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
Already premium?